Lymphoproliferative Disorder in an Esophageal Cancer Patient Treated with Pembrolizumab
-
- Matsumura Takashi
- Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan
-
- Tsuchihashi Kenji
- Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan
-
- Yamamoto Takeo
- Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Japan
-
- Jinnouchi Fumiaki
- Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan
-
- Kusano Wataru
- Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan
-
- Kusumoto Yota
- Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan
-
- Arimizu Kohei
- Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan
-
- Ohmura Hirofumi
- Department of Comprehensive Oncology, Graduate School of Medical Sciences, Kyushu University, Japan
-
- Kuma Yuki
- Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Japan
-
- Moriyama Shohei
- Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan
-
- Yamaguchi Kyoko
- Department of Medical Education, Graduate School of Medical Science, Kyushu University, Japan
-
- Ito Mamoru
- Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan
-
- Isobe Taichi
- Department of Comprehensive Oncology, Graduate School of Medical Sciences, Kyushu University, Japan
-
- Ariyama Hiroshi
- Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan
-
- Oda Yoshinao
- Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Japan
-
- Akashi Koichi
- Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan
-
- Baba Eishi
- Department of Comprehensive Oncology, Graduate School of Medical Sciences, Kyushu University, Japan
Description
<p>A 75-year-old man diagnosed with esophageal cancer and lung metastasis received a combination of fluorouracil, cisplatin, and pembrolizumab. During pembrolizumab maintenance therapy, lymphoproliferative lesions at the lips and mouth and multiple lymph node swellings appeared. Histologically, Epstein-Barr virus (EBV)-encoded RNA was positive, and EBV-DNA was detected in the blood. The patient was diagnosed with other iatrogenic immunodeficiency-associated lymph proliferative disorders (OIIA-LPDs) related to EBV activation induced by pembrolizumab. Rituximab was administered, resulting in the improvement of the OIIA-LPD. The emergence of an OIIA-LPD merits close attention in patients receiving immune checkpoint inhibitors. </p>
Journal
-
- Internal Medicine
-
Internal Medicine advpub (0), 2024
The Japanese Society of Internal Medicine